Superiority of Docetaxel plus Capecitabine Compared to Docetaxel plus Epirubicin as First-Line Therapy for Metastatic Breast Cancer - Final Results of the ERASME-4 Study.

被引：0
|
作者：
Bachelot, T.
Bajard, A.
Ray-Coquard, I
Coeffic, D.
Dramais, D.
Ferri-Dessens, R.-M.
Guastalla, J.-P.
Perol, D.
机构：
[1] Ctr Leon Berard, F-69373 Lyon, France
[2] Ctr Hosp, Annecy, France
[3] Inst Daniel Hollard, Grenoble, France
[4] Ctr Hosp, Valence, France
[5] Roche France, Paris, France
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：625S / 625S
页数：1
相关论文
共 50 条
  • [21] COMPARATIVE EFFICACY OF FIRST-LINE DOCETAXEL plus CAPECITABINE (XT) VERSUS DOCETAXEL plus EPIRUBICIN (ET): POOLED ANALYSIS OF TWO RANDOMISED TRIALS
    Luporsi, E.
    Bachelot, T.
    Bajard, A.
    Chinal, J. Provencal
    Coeffic, D.
    Platini, C.
    Marcel, D. Dramais
    Oprea, C.
    Ferri-Dessems, R.
    Perol, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 67 - 68
  • [22] Docetaxel with epirubicin as first line chemotherapy in metastatic breast cancer (MBC).: Final results of a Phase II study
    Morales, S
    Lorenzo, A
    Ramos, M
    Ballesteros, P
    Méndez, M
    Almanza, C
    Moreno-Nogueira, J
    Casal, J
    Castellanos, J
    Lizón, J
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S68 - S68
  • [23] Final results of a phase II study of bevacizumab plus docetaxel for the first-line treatment of metastatic breast cancer (TORT-B01)
    Hurvitz, S.
    Allen, H. J.
    Moroose, R. L.
    Chan, D.
    Hagenstad, C.
    Applebaum, S. H.
    Patel, G.
    Hu, E. H.
    Slamon, D. J.
    Kabbinavar, F.
    EJC SUPPLEMENTS, 2008, 6 (07): : 217 - 217
  • [24] Vinorelbine (V) plus docetaxel (D) followed by Capecitabine (C) as first-line treatment of metastatic breast cancer (MBC)
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 168 - 169
  • [25] Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer
    Saeki T.
    Takashima S.
    Breast Cancer, 2004, 11 (2) : 116 - 120
  • [26] A multicenter phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first line treatment in patients with locally advanced and metastatic breast cancer. Preliminary report
    Mavroudis, D
    Boukovinas, I
    Ardavanis, A
    Syrigos, K
    Kouroussis, CH
    Kakolyris, S
    Malamos, N
    Athanasiadis, A
    Varthalitis, I
    Potamianou, A
    Georgoulias, V
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S280 - S280
  • [27] Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II study
    Abudureheiyimu, Nilupai
    Wu, Yun
    Li, Qing
    Zhang, Pin
    Ma, Fei
    Yuan, Peng
    Luo, Yang
    Fan, Ying
    Chen, Shanshan
    Cai, Ruigang
    Li, Qiao
    Han, Yiqun
    Xu, Hangcheng
    Wang, Yan
    Wang, Jiayu
    JOURNAL OF THE NATIONAL CANCER CENTER, 2023, 3 (02): : 115 - 120
  • [28] Feasibility of docetaxel, epirubicin, and capecitabine (TEX) plus pegfilgrastim as neoadjuvant treatment for primary breast cancer: A pilot study.
    Wenzel, C
    Hussian, D
    Bartsch, R
    Pluschnig, U
    Locker, GJ
    Gnant, M
    Jakesz, R
    Zielinski, CC
    Steger, GG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 55S - 55S
  • [29] Retrospective analysis of docetaxel, oxaliplatin plus fluorouracil compared with epirubicin, cisplatin and fluorouracil as first-line therapy for advanced gastric cancer
    Yao, Zhihua
    Guo, Hongqiang
    Yuan, Yadong
    Zhao, Yan
    Yao, Shuna
    Xu, Yingjun
    Liu, Lei
    Liu, Tao
    Liu, Yanyan
    Yang, Shujun
    JOURNAL OF CHEMOTHERAPY, 2014, 26 (02) : 117 - 121
  • [30] Docetaxel versus epirubicin/cyclophosphamide (EC) as first-line therapy in metastatic breast cancer (MBC): Results from the randomized phase II TIPP study.
    Wasemann, C
    Ertan, A
    Strunck, C
    Schmidt, W
    Diedrich, K
    Friedrich, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 82S - 82S
12345